Advanced search
Add to list

Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy

(2003) ARTHRITIS AND RHEUMATISM. 48(4). p.1015-1023
Author
Organization
Abstract
Objective. To investigate the effect of infliximab treatment on antinuclear antibodies (ANAs), anti-double-stranded DNA (anti-dsDNA), antinucleosome, antihistone, and anti-extractable nuclear antigen (anti-ENA) antibodies in rheumatoid arthritis (RA) and spondylarthropathy (SpA) patients. Methods. Sera from 62 RA and 35 SpA patients treated with infliximab were tested at baseline and week 30 (RA group) or week 34 (SpA group). ANAs were tested by indirect immunofluorescence (IIF) on HEp-2 cells. Anti-dsDNA antibodies were detected by IIF on Crithidia luciliae and by enzyme-linked immunosorbent assay (ELISA) and were further isotyped with gamma, mu, and a chain-specific conjugates at various time points. Antinucleosome antibodies were tested by ELISA. Anti-histone and anti-ENA antibodies were detected by line immunoassay. Results. Initially, 32 of 62 RA patients and 6 of 35 SpA patients tested positive for ANAs. After infliximab treatment, these numbers shifted to 51 of 62 (P < 0.001) and 31 of 35 (P < 0.001), respectively. At baseline, none of the RA or SpA patients had anti-dsDNA antibodies. After infliximab treatment, 7 RA patients (P = 0.016) and 6 SpA patients (P = 0.031) became positive for anti-dsDNA antibodies. All 7 anti-dsDNA-positive RA patients had IgM and IgA anti-dsDNA antibodies. Three of the 6 anti-dsDNA-positive SpA patients had IgM and IgA anti-dsDNA antibodies, and 2 had IgM anti-dsDNA antibodies alone. In both diseases, the IgM anti-dsDNA antibodies appeared before the IgA anti-dsDNA antibodies. During the observation period, no IgG anti-dsDNA antibodies or lupus symptoms were observed. The development of antinucleosome, antihistone, or anti-ENA antibodies following infliximab treatment was observed in some patients, but the numbers were not statistically significant. Conclusion. Infliximab treatment may induce ANAs, and especially IgM and IgA anti-dsDNA antibodies, in RA and SpA patients. However, no anti-dsDNA IgG antibodies or lupus symptoms were observed during the period of observation in this study, and the development of antinucleosome, antihistone, or anti-ENA antibodies was not statistically significant. These observations do not exclude potential induction of clinically significant lupus in the long term, and further followup is therefore mandatory.
Keywords
SYSTEMIC-LUPUS-ERYTHEMATOSUS, NECROSIS-FACTOR-ALPHA, CHIMERIC MONOCLONAL-ANTIBODY, ACTIVE ANKYLOSING-SPONDYLITIS, ETANERCEPT THERAPY, CROHNS-DISEASE, RECEIVING METHOTREXATE, REVISED CRITERIA, DSDNA ANTIBODIES, DNA ANTIBODIES

Citation

Please use this url to cite or link to this publication:

MLA
De Rycke, Leen, et al. “Antinuclear Antibodies Following Infliximab Treatment in Patients with Rheumatoid Arthritis or Spondylarthropathy.” ARTHRITIS AND RHEUMATISM, vol. 48, no. 4, 2003, pp. 1015–23.
APA
De Rycke, L., Kruithof, E., Van Damme, N., Hoffman, I., VAN DEN BOSSCHE, N., Van den Bosch, F., … De Keyser, F. (2003). Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. ARTHRITIS AND RHEUMATISM, 48(4), 1015–1023.
Chicago author-date
De Rycke, Leen, Elli Kruithof, Nancy Van Damme, Ilse Hoffman, N VAN DEN BOSSCHE, Filip Van den Bosch, Eric Veys, and Filip De Keyser. 2003. “Antinuclear Antibodies Following Infliximab Treatment in Patients with Rheumatoid Arthritis or Spondylarthropathy.” ARTHRITIS AND RHEUMATISM 48 (4): 1015–23.
Chicago author-date (all authors)
De Rycke, Leen, Elli Kruithof, Nancy Van Damme, Ilse Hoffman, N VAN DEN BOSSCHE, Filip Van den Bosch, Eric Veys, and Filip De Keyser. 2003. “Antinuclear Antibodies Following Infliximab Treatment in Patients with Rheumatoid Arthritis or Spondylarthropathy.” ARTHRITIS AND RHEUMATISM 48 (4): 1015–1023.
Vancouver
1.
De Rycke L, Kruithof E, Van Damme N, Hoffman I, VAN DEN BOSSCHE N, Van den Bosch F, et al. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. ARTHRITIS AND RHEUMATISM. 2003;48(4):1015–23.
IEEE
[1]
L. De Rycke et al., “Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy,” ARTHRITIS AND RHEUMATISM, vol. 48, no. 4, pp. 1015–1023, 2003.
@article{209247,
  abstract     = {{Objective. To investigate the effect of infliximab  treatment on antinuclear  antibodies (ANAs), anti-double-stranded DNA (anti-dsDNA), antinucleosome, antihistone, and anti-extractable nuclear antigen (anti-ENA) antibodies in rheumatoid arthritis  (RA) and spondylarthropathy (SpA) patients.

Methods. Sera from 62 RA and 35 SpA patients treated with infliximab were tested at baseline and week 30 (RA group) or week 34 (SpA group). ANAs were tested by indirect immunofluorescence (IIF) on HEp-2 cells. Anti-dsDNA antibodies were detected by IIF on Crithidia luciliae and by enzyme-linked immunosorbent assay (ELISA) and were further isotyped with gamma, mu, and a chain-specific conjugates at various time points. Antinucleosome antibodies were tested by ELISA. Anti-histone and anti-ENA antibodies were detected by line immunoassay.

Results. Initially, 32 of 62 RA patients and 6 of 35 SpA patients tested positive for ANAs. After infliximab treatment, these numbers shifted to 51 of 62 (P < 0.001) and 31 of 35 (P < 0.001), respectively. At baseline, none of the RA or SpA patients had anti-dsDNA antibodies. After infliximab treatment, 7 RA patients (P = 0.016) and 6 SpA patients (P = 0.031) became positive for anti-dsDNA antibodies. All 7 anti-dsDNA-positive RA patients had IgM and IgA anti-dsDNA antibodies. Three of the 6 anti-dsDNA-positive SpA patients had IgM and IgA anti-dsDNA antibodies, and 2 had IgM anti-dsDNA antibodies alone. In both diseases, the IgM anti-dsDNA antibodies appeared before the IgA anti-dsDNA antibodies. During the observation period, no IgG anti-dsDNA antibodies or lupus symptoms were observed. The development of antinucleosome, antihistone, or anti-ENA antibodies following infliximab treatment was observed in some patients, but the numbers were not statistically significant.

Conclusion. Infliximab treatment may induce ANAs, and especially IgM and IgA anti-dsDNA antibodies, in RA and SpA patients. However, no anti-dsDNA IgG antibodies or lupus symptoms were observed during the period of observation in this study, and the development of antinucleosome, antihistone, or anti-ENA antibodies was not statistically significant. These observations do not exclude potential induction of clinically significant lupus in the long term, and further followup is therefore mandatory.}},
  author       = {{De Rycke, Leen and Kruithof, Elli and Van Damme, Nancy and Hoffman, Ilse and VAN DEN BOSSCHE, N and Van den Bosch, Filip and Veys, Eric and De Keyser, Filip}},
  issn         = {{0004-3591}},
  journal      = {{ARTHRITIS AND RHEUMATISM}},
  keywords     = {{SYSTEMIC-LUPUS-ERYTHEMATOSUS,NECROSIS-FACTOR-ALPHA,CHIMERIC MONOCLONAL-ANTIBODY,ACTIVE ANKYLOSING-SPONDYLITIS,ETANERCEPT THERAPY,CROHNS-DISEASE,RECEIVING METHOTREXATE,REVISED CRITERIA,DSDNA ANTIBODIES,DNA ANTIBODIES}},
  language     = {{eng}},
  number       = {{4}},
  pages        = {{1015--1023}},
  title        = {{Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy}},
  volume       = {{48}},
  year         = {{2003}},
}

Web of Science
Times cited: